Establishment of a staging model for Parkinson's disease in mice

被引:1
|
作者
Tian, Yueqin [1 ]
Xian, Jianhua [2 ]
Tian, Yuehua [3 ]
Gao, Xiaoya [1 ,4 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Neurol, Guangzhou 510282, Guangdong, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Dermatol, Guangzhou 510400, Guangdong, Peoples R China
[3] Kangyuan Hosp, Dept Internal Med, Guangzhou 510440, Guangdong, Peoples R China
[4] Southern Med Univ, Zhujiang Hosp, Dept Pediat Neurol, Guangzhou, Guangdong, Peoples R China
关键词
Parkinson's disease; staging mo; del; MPTP; C57; BL6; mice; ANIMAL-MODELS; MPTP; DEGENERATION; PATHOLOGY; EXPOSURE;
D O I
10.14715/cmb/2023.69.4.22
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease is the second most common neurodegenerative disease with different pathological mechanisms at each stage. To investigate Parkinson's disease further, this study proposed to develop a continuous staging mouse model of Parkinson's disease to reproduce the pathological features of different stages of Parkinson's disease. We successively treated the mice with MPTP and assessed the behavioral performance of the mice with the open field test and the rotarod test, and detected the aggregation of & alpha;-syn and the expression of TH protein in the substantia nigra of the mice with western blot test and immunofluorescence test. The results showed that the mice injected with MPTP for 3 days had no significant behavioral changes, and no significant & alpha;-syn aggregation, but reduced TH protein expression and 39.5% loss of dopaminergic neurons in the substantia nigra, similar to the performance in the prodromal phase of Parkinson's disease. However, the behavior of the mice continuously treated with MPTP for 14 days was significantly altered, with significant & alpha;-syn aggregation, a significant reduction in TH protein expression, and 58.1% loss of dopaminergic neurons in the substantia nigra, corresponding to the early clinical stage of Parkinson's disease. In the mice that were exposed to MPTP for 21 days, the motor impairment was more obvious, the & alpha;-syn aggregation was more significant, the reduction of TH protein expression was more evident, and the loss of dopaminergic neurons reached 80.5% in the substantia nigra, showing a clinical progression similar to that of Parkinson's disease. Consequently, this study found that continuous treatment of C57/BL6 mice with MPTP for 3, 14 and 21 days could construct mouse models of prodromal, early clinical and clinical progressive stages of Parkinson's disease, respectively, providing a promising experimental model foundation for the study of the different stages of Parkinson's disease.
引用
收藏
页码:141 / 146
页数:6
相关论文
共 50 条
  • [1] Establishment of a new mice model of Parkinson's disease exhibiting decreased locomotive activity
    Sakata, Shinichi
    Hattori, Nobutaka
    Iwai, Kazuhiro
    [J]. NEUROSCIENCE RESEARCH, 2010, 68 : E192 - E192
  • [2] Frontostriatal Cognitive Staging in Parkinson's Disease
    de la Fuente-Fernandez, Raul
    [J]. PARKINSONS DISEASE, 2012, 2012
  • [3] α-Synuclein staging in the amygdala of a Parkinson's disease model: cell types involved
    Flores-Cuadrado, Alicia
    Ubeda-Banon, Isabel
    Saiz-Sanchez, Daniel
    de la Rosa-Prieto, Carlos
    Martinez-Marcos, Alino
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2015, 41 (01) : 137 - 146
  • [4] Brain Stem Pathology in Parkinson's Disease: An Evaluation of the Braak Staging Model
    Kingsbury, Ann E.
    Bandopadhyay, Rina
    Silveira-Moriyama, Laura
    Ayling, Hilary
    Kallis, Constantinos
    Sterlacci, William
    Maeir, Hans
    Poewe, Werner
    Lees, Andrew J.
    [J]. MOVEMENT DISORDERS, 2010, 25 (15) : 2508 - 2515
  • [5] Restoration of Noradrenergic Function in Parkinson's Disease Model Mice
    Cui, Kui
    Yang, Fan
    Tufan, Turan
    Raza, Muhammad U.
    Zhan, Yanqiang
    Fan, Yan
    Zeng, Fei
    Brown, Russell W.
    Price, Jennifer B.
    Jones, Thomas C.
    Miller, Gary W.
    Zhu, Meng-Yang
    [J]. ASN NEURO, 2021, 13
  • [6] Mice with disrupted mitochondria used to model Parkinson’s disease
    Zak Doric
    Ken Nakamura
    [J]. Nature, 2021, 599 (7886) : 558 - 560
  • [7] Intranasal Stem Cells for Parkinson's Disease Model in Mice
    Sabry, Dina
    Salama, Mohamed
    Sobh, Mahmoud
    Emam, Mahmoud
    El-Gamal, Mohamed
    Abdalla, Ahmed
    Lotfy, Ahmed
    El-Qotb, Mahmoud
    Sobh, Mohamed
    [J]. NEUROLOGY, 2016, 86
  • [8] Protective abilities of ibuprofen in the mice model of Parkinson’s disease
    Maciej Świątkiewicz
    Małgorzata Zaremba
    Ilona Joniec
    Andrzej Członkowski
    Iwona Kurkowska-Jastrzębska
    [J]. Pharmacological Reports, 2013, 65 (Suppl 1) : 92 - 93
  • [9] The establishment of a mouse model of Parkinson's disease induced by intranasal administration of LPS
    Song, G. B.
    Xi, G. P.
    Li, Y. H.
    Li, K. J.
    Liu, J. C.
    Chai, Z.
    Huang, J. J.
    Xiao, B. G.
    Zhang, G. X.
    Ma, C. G.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 198 - 199
  • [10] Staging of α-Synuclein in the Olfactory Bulb in a Model of Parkinson's Disease: Cell Types Involved
    Ubeda-Banon, Isabel
    Saiz-Sanchez, Daniel
    de la Rosa-Prieto, Carlos
    Mohedano-Moriano, Alicia
    Fradejas, Noelia
    Calvo, Soledad
    Argandona-Palacios, Lucia
    Garcia-Munozguren, Susana
    Martinez-Marcos, Alino
    [J]. MOVEMENT DISORDERS, 2010, 25 (11) : 1701 - 1707